CASI Pharmaceuticals Inc CASI

Healthcare Biotechnology

CASI Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company is focused on acquiring, developing, and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. Its commercial product, EVOMELA, is an intravenous formulation of melphalan commercialized by Acrotech in the multiple myeloma treatment setting in the United States. Its pipeline products include CNCT19 (CD19 CAR-T), BI-1206 (anti- FcYRIIB antibody), CB-5339 (VCP/p97 inhibitor), CID-103 (Anti-CD38 Mab), Thiotepa, and Octreotide LAI. The Company’s Food and Drug Administration (FDA)-approved generic products for the China market include Entecavir tablets, Tenofovir disoproxil fumarate (TDF) tablets, Cilostazol tablets-50mg, Cilostazol tablets-100mg, Ondansetron HCL tablets, and Tizanidine tablets.

NDAQ:CASI - Post by User

CASI Pharmaceuticals Inc

Bullboard Posts

Post by mhoganon Feb 26, 2000 12:18pm

130 Views

Post# 1452624

Update

On Wednesday, ENMD announced the issuance of a broad patent, covering all antiangiogenic fragments and methods of production for its potent angiogenesis inhibitor, angiostatin protein. ENMD now has patent protection covering all forms of the angiostatin molecule, whether used as a protein, peptide fragment, or gene for delivery to a patient.

Bullboard Posts

Three micro-cap value stocks trading at peak pessimism